Press release BoxID: 628862 (Xenios AG)
  • Xenios AG
  • Im Zukunftspark 1
  • 74076 Heilbronn
  • Contact person
  • Franziska Auerbach
  • +49 (7131) 2706-114

Xenios AG acquires Ilias Medical GmbH

(PresseBox) (Heilbronn, ) Novalung GmbH and Medos AG recently joined forces to establish Xenios AG in order to accelerate their strategy to become market leader and technology leader in extracorporeal therapies.

Xenios AG today reported that it acquired Ilias Medical GmbH, formerly based in Bochum, Germany, in June 2013. This acquisition is part of the Xenios growth strategy. The Ilias technologies, including a one-of-a-kind portable organ support console, will further expand Xenios' leading portfolio of extracorporeal therapies for respiratory support and cardiopulmonary bypass. Josef Bogenschütz, CEO of Xenios AG, commented: "We are pleased that by acquiring Ilias Medical GmbH we have created a new technological and innovative option with further perspectives for the application of mobile systems for cardiac and pulmonary support."

The Ilias technology will further accelerate the expansion of Xenios into new business areas and therapies with its extracorporeal technologies. The groundbreaking Ilias Xtravent System is by far the lightest and most compact extracorporeal therapy system worldwide, and Georg Matheis, CSO of Xenios AG, explained: "The acquisition of Ilias is a further step towards a paradigm shift regarding extracorporeal cardiopulmonary support. We are implementing our Xenios growth strategy by providing the clinical team with innovative therapy systems. These systems open the doors to a paradigm shift in the field of extracorporeal therapies." The deal includes all assets and intellectual property of Ilias. The transfer of the Ilias assets to the Xenios headquarters in Heilbronn, Germany, was already completed in July.

"With the takeover of Ilias Medical GmbH we are consequently extending our portfolio of innovative technologies according to our aspirations to become the future drivers for innovation in the field of extracorporeal therapy", Xenios CMMO Jürgen Böhm explained.